The Role Of Soluble Transferrin Receptor In The Regulation Of Iron Homeostasis
Funder
National Health and Medical Research Council
Funding Amount
$539,607.00
Summary
Iron is both essential for health and toxic in excess so the body very tightly regulates how much iron is absorbed from the diet. One of the most important regulators of dietary iron absorption is the iron demands of developing red blood cells. In this project we will investigate how developing red blood cells signal changes in iron absorption. An understanding of this process will be of great benefit in the analysis and treatment of important blood diseases and disorders of iron metabolism.
A Universal Clinical Test For Gene Fusions In Blood Cancer
Funder
National Health and Medical Research Council
Funding Amount
$628,001.00
Summary
Mis-repair of broken chromosomes results in gene fusion and is a common feature of blood cancers. Current tests are only capable of detecting well-known gene fusions and are incapable of identifying new fusion events or fusion variations. We have developed a scientific technique, termed CaptureSeq, that can address these issues. We propose to use this technique as the foundation for a single clinical test for blood cancers, capable of detecting all possible fusion variations – known and unknown.
Regulation Of Megakaryocyte And Platelet Survival In Malignancy
Funder
National Health and Medical Research Council
Funding Amount
$536,914.00
Summary
In this grant we will investigate how blood cells called platelets are produced in normal conditions and during disease. Platelets are blood cells that stop us from bleeding when we get a cut. When too many platelets accumulate, there is an increased risk of blood clots forming. This project grant will help us learn how platelet numbers swell in response to some blood and ovarian cancers, and the mechanisms that control cell death in platelets and the cells that produce them.
Long-term In Vivo Imaging Of Bone Marrow Microenvironments In Multiple Myeloma.
Funder
National Health and Medical Research Council
Funding Amount
$688,371.00
Summary
White blood cells are soldiers of the immune system. When the machinery that controls growth and death of these cells is disrupted, these cells can undergo massive expansion. This leads to the development of blood cancers such as multiple myeloma (MM). In MM, malignant cells infiltrate bones preventing production of blood and damaging the bone structure leading to fractures. Using cutting edge microcopy we will watch how MM cells grow and damage bone tissue to develop new therapeutic approaches.
The Targeting Of Flt3, C-Kit And Src As Therapies For C-Cbl-associated Myeloid Malignancies
Funder
National Health and Medical Research Council
Funding Amount
$535,416.00
Summary
Most leukaemias are incurable so it is important to find new treatments. For this to occur it is essential that the mutated genes causing leukaemia are identified. We have generated a mouse with a mutation in a gene, c-Cbl, that promotes the activation of a number of proteins involved in leukaemia development. By treating c-Cbl mutant mice with drugs that target these proteins we intend to identify the most effective treatments for human leukaemias associated with c-Cbl mutations.
The Role Of Duffy And PF4 In The Platelet Killing Of Malaria Parasites.
Funder
National Health and Medical Research Council
Funding Amount
$350,045.00
Summary
Platelets in the blood can kill the Plasmodium parasite, which lives inside red blood cells and causes malaria. Platelets bind parasite-infected red cells and release a molecule that is toxic to the parasite. This project will study why a red cell molecule called Duffy is also needed for this function of platelets. Most Africans carry a gene for Duffy that stops its expression in red cells, and may therefore be more susceptible to malaria because their platelets cannot kill the malaria parasite.
Identifying Novel Antimalarial Targets Using ENU Mutagenesis In The Mouse
Funder
National Health and Medical Research Council
Funding Amount
$760,170.00
Summary
Malaria is estimated to cause 1.2 million deaths per year. The malarial parasite has developed resistance to most drugs and new drugs are needed. We aim to mimic the protective red blood cell diseases common in human populations in malarial endemic areas by identifying host targets that are important in parasite growth.
Chemotherapy causes a massive depletion of blood-producing cells in the bone marrow. This results in a condition known as myelosuppression that has many harmful side effects for cancer patients. Our aim is to develop a safe and inexpensive approach that will specifically protect the blood-producing cells from chemotherapy but leave the cancer cells sensitive. If this treatment shows significant benefits in mouse models of cancer then the establishment of clinical trials will be initiated.
Griseofulvin, A Novel Host-directed Antimalarial Drug
Funder
National Health and Medical Research Council
Funding Amount
$461,551.00
Summary
This grant is for a Phase II clinical trial to test an FDA & TGA approved drug for a new use as an antimalarial drug. The parasite uses an enzyme from the human RBC to help it replicate & early trials show this drug appears to disrupt the life cycle of the parasite. This Phase II clinical trial will test the drug on human subjects, & if successful, the drug will be a new and novel way in which to treat and prevent malarial infections in humans.
Genetics Of Complex Traits In Multiply Phenotyped Twin Sibships: The Brisbane Longitudinal Twin Study
Funder
National Health and Medical Research Council
Funding Amount
$1,019,887.00
Summary
Our aim is to identify genes influencing common diseases including melanoma, asthma and cardiovascular disease. We measure adolescent twins for moliness, skin, hair and eye colour and a variety of blood traits. We have already found new genes for mole count, eye colour, skin damage, and several different blood cell types. For each of these disease traits there are many more genes to be found and these will inform new treatments. We plan to keep expanding our sample size achieve this.